DEALS: AstraZeneca, Pozen in $375M licensing deal

DEALS

WHO

WITH

WHAT

SCOOP

AstraZeneca

Pozen

$375M licensing deal

The companies will co-develop remedies for chronic pain utilizing Pozen's technology. Pozen gets $40 million up front and up to $335 million in additional milestone payments.

Amgen

Predix

$307M licensing deal

Amgen will pay an initial $20 million for Predix's autoimmune disease treatment and up to an additional $287.5 million in milestone payments.

Nextar

Affymax

$17.6M licensing agreement

Nektar is providing Affymax with technology to develop Hematide. The deal was previously undisclosed.

YM BioSciences

Daiichi Pharmaceutical

$14.5M licensing deal

YM BioSciences has licensed developing and marketing rights for nimotuzumab for an up-front payment of $14.5 million plus additional milestone payments.

Archemix

Nuvelo

collaboration

Archemix and Nuvelo have expanded their collaboration. Archemix will be responsible for research and Nuvelo will be responsible for development and commercialization.

Enzon

Santaris

collaboration

Enzon will develop and commercialize a series of RNA antagonists based on Santaris technology.

Avalon

ChemDiv

collaboration

The companies are collaborating for the discovery and development of small molecule oncology therapeutics.

Eli Lilly

Alcon

collaboration

The companies signed a long-term agreement to co-promote ruboxistaurin mesylat.

Biovail

Athpharma

partnership

The companies are ending their development partnership for four cardiovascular drugs.

Dainippon Sumitomo

Bristol-Myers K.K.

partnership

Bristol-Myers will license to Dainippon the development rights of irbesartan.  Dainippon will grant Bristol-Myers with co-marketing rights of miriplatin hydrate.

Receptor BioLogix

Aphton

acquisition

Receptor BioLogix has acquired the cancer vaccine Insegia and related assets from Aphton in a Chapter 11 sale.

Cambridge Antibody Technology

Enzon

acquisition

Cambridge acquired the license to CAT-5001 from Enzon.

Iconix

Merck KGaA

services agreement

Iconix will compare several of Merck's compounds to similar products to gain insight into the safety of new drug candidates in the early stages of pre-clinical development.